United Therapeutics Corp [NASDAQ: UTHR] slipped around -7.46 points on Friday, while shares priced at $358.93 at the close of the session, down -2.04%.
Compared to the average trading volume of 320.47K shares, UTHR reached a trading volume of 247912 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about United Therapeutics Corp [UTHR]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for UTHR shares is $400.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on UTHR stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for United Therapeutics Corp shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on July 11, 2024. While these analysts kept the previous recommendation, Goldman raised their target price from $213 to $215. The new note on the price target was released on February 12, 2024, representing the official price target for United Therapeutics Corp stock. Previously, the target price had yet another raise to $330, while Leerink Partners analysts kept a Outperform rating on UTHR stock.
The Average True Range (ATR) for United Therapeutics Corp is set at 9.16, with the Price to Sales ratio for UTHR stock in the period of the last 12 months amounting to 5.81. The Price to Book ratio for the last quarter was 2.62, with the Price to Cash per share for the same quarter was set at 74.51. Price to Free Cash Flow for UTHR in the course of the last twelve months was 17.84 with Quick ratio for the last quarter at 4.41.
How has UTHR stock performed recently?
United Therapeutics Corp [UTHR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.65. With this latest performance, UTHR shares dropped by -3.73% in over the last four-week period, additionally plugging by 9.21% over the last 6 months – not to mention a rise of 61.50% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for UTHR stock in for the last two-week period is set at 45.95, with the RSI for the last a single of trading hit 44.69, and the three-weeks RSI is set at 46.88 for United Therapeutics Corp [UTHR]. The present Moving Average for the last 50 days of trading for this stock 370.09, while it was recorded at 362.91 for the last single week of trading, and 326.70 for the last 200 days.
United Therapeutics Corp [UTHR]: Deeper insight into the fundamentals
United Therapeutics Corp’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.41 and a Current Ratio set at 4.58.
Earnings analysis for United Therapeutics Corp [UTHR]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for UTHR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for United Therapeutics Corp go to 13.64%.
Insider trade positions for United Therapeutics Corp [UTHR]
There are presently around $99.95%, or 101.83%% of UTHR stock, in the hands of institutional investors. The top three institutional holders of UTHR stocks are: BLACKROCK INC. with ownership of 5.47 million shares, which is approximately 11.6362%. VANGUARD GROUP INC, holding 4.42 million shares of the stock with an approximate value of $$1.41 billion in UTHR stocks shares; and VANGUARD GROUP INC, currently with $$1.05 billion in UTHR stock with ownership which is approximately 6.99%.
